SavedAdd your journal

Journals / Turkish Journal of Pediatrics / 2021 / Cilt: 63 - Sayı: 2

Rare presentation of levamisole-induced leukoencephalopathy in a pediatric patient: seizure

Cem PAKETÇİ
Derya OKUR
Semra HIZ
Uluç YİŞ
Pages
319–322
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Levamisole-induced leukoencephalopathy should be considered in the differential diagnosis of demyelinating diseases, the neurotoxic effects of the drug should be well understood, and treatment should be initiated as soon as possible.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Levamisole is an imidazole derivative used in the treatment of various cancers, dermatological diseases, and parasitosis.
📊
Key Findings & Data:Illegal use of levamisole by mixing it with cocaine in order to increase the psychotropic effects has also increased in recent years.
💡
Conclusion & Impact:Levamisole-induced leukoencephalopathy should be considered in the differential diagnosis of demyelinating diseases, the neurotoxic effects of the drug should be well understood, and treatment should be initiated as soon as possible.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Background. Levamisole is an imidazole derivative used in the treatment of various cancers, dermatological diseases, and parasitosis. Illegal use of levamisole by mixing it with cocaine in order to increase the psychotropic effects has also increased in recent years. Leukoencephalopathy is one of levamisole’s most prominent neurological side effects. Case. Here we present the clinical, laboratory, imaging findings, treatment, and follow-up information of a 12-year-old girl who presented with seizures due to levamisole, which was prescribed to treat vitiligo. Conclusion. Levamisole-induced leukoencephalopathy should be considered in the differential diagnosis of demyelinating diseases, the neurotoxic effects of the drug should be well understood, and treatment should be initiated as soon as possible.

🔖

Cite This Article

PAKETÇİ, C., OKUR, D., HIZ, S., YİŞ, U. (2021). Rare presentation of levamisole-induced leukoencephalopathy in a pediatric patient: seizure. Turkish Journal of Pediatrics, Cilt: 63 - Sayı: 2, 319–322. https://ajindex.com/articles/411956

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Amery WK, Bruynseels JP. Levamisole, the story and the lessons. Int J Immunopharmacol 1992; 14: 481-486
  2. Scheinfeld N, Rosenberg JD, Weinberg JM. Levamisole in dermatology: a review. Am J Clin Dermatol 2004; 5: 97-104
  3. Cheng YC, Po HL. Leukoencephalopathy after levamisole for the treatment of verrucae. Acta Neurol Taiwan 2011; 20: 262-266
  4. Larocque A, Hoffman RS. Levamisole in cocaine: unexpected news from an old acquaintance. Clin Toxicol (Phila) 2012; 50: 231-241
  5. Brunt TM, van den Berg J, Pennings E, Venhuis B. Adverse effects of levamisole in cocaine users: a review and risk assessment. Arch Toxicol 2017; 91: 2303-2313
  6. Xu N, Zhou W, Li S, Zhou G, Zhang N, Liang J. Clinical and MRI characteristics of levamisole- induced leukoencephalopathy in 16 patients. J Neuroimaging 2009; 19: 326-331
  7. WuVC,HuangJW,LienHC,etal.Levamisole-induced multifocal inflammatory leukoencephalopathy: clinical characteristics, outcome, and impact of treatment in 31 patients. Medicine (Baltimore) 2006; 85: 203-213
  8. Aberastury MN, Silva WH, Vaccarezza MM, Maxit C, Agosta G. Epilepsia partialis continua associated with levamisole. Pediatr Neurol 2011; 44: 385-388
  9. Yan R, Wu Q, Ren J, et al. Clinical features and magnetic resonance image analysis of 15 cases of demyelinating leukoencephalopathy induced by levamisole. Exp Ther Med 2013; 6: 71-74